News Column

Dompe announces the Food and Drug Administration FDA has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis

August 6, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Dompe, a leader in R&D for new therapeutic solutions for the treatment of rare diseases, announces that rhNGF (Recombinant Human Nerve Growth Factor) has been designated as an orphan drug by the American Food and Drug Administration (FDA) (see also Dompe).

http://photos.prnewswire.com/prnvar/20140722/129575

The candidate drug, developed by the research of Dompe, has been designated as an orphan drug for the treatment of neurotrophic keratitis, a degenerative corneal disease that affects less than 1 in 5,000 people(1) and is currently without a cure. This is the second orphan drug designation by the FDA for rhNGF, after the recent designation for the treatment of retinitis pigmentosa, a rare genetic disease that affects more than 1 million people worldwide(2).

This acknowledgment represents an important step in the clinical development of the drug, which is currently in advanced stages of experimentation for the treatment of neurotrophic keratitis in the REPARO study. The randomized, double-blind study includes 39 centers in 9 European countries (Italy, Great Britain, Germany, France, Belgium, Spain, Portugal, Poland, Hungary) and involves patients suffering from unilateral neurotrophic keratitis with grade 2 lesions (persistent epithelial defect) or grade 3 lesions (corneal ulcers) that do not respond to the currently available medical treatment. The objective of the trial is to evaluate the safety, tolerability, and effectiveness of two different doses of recombinant human nerve growth factor (rhNGF) compared to the placebo. The more than 170 patients enrolled in the study are divided into three different groups, treated respectively with two different doses of rhNGF and with the placebo. The secondary objectives include the evaluation of corneal lesion healing, improvement in visual acuity, and the sensitivity of the cornea.

"We are particularly proud of this new FDA designation, which represents an important recognition of our Research & Development efforts in the field of ophthalmology on a global scale, particularly in North America," - explains Eugenio Aringhieri, CEO of the Dompe Group. "It is another confirmation of the constant dialogue with the international regulatory agencies in order to bring health issues that still need to be resolved to the forefront as well as possible therapeutic solutions for diseases that are currently without a cure. This is the direction that the efforts of our Group is taking, focused on the identification of innovative drugs to protect patients around the world."

rhNGF is the result of a specific research project at the Dompe Center for Research & Development of l'Aquila and is produced using recombinant DNA technology, or by transferring human genetic material into bacterial DNA, enabling the bacteria to produce NGF that is entirely identical to that naturally produced by the human body.

Keywords for this news article include: Dompe, Genetics, Keratitis, Ophthalmology, Regulatory Agencies, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters